Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Kreutzman, Anna ^a   Rohon, Peter ^a,b   Faber, Edgar ^b   Indrak, Karel ^b   Juvonen, Vesa ^c   Kairisto, Veli ^c   Voglová, Jaroslava ^d   Sinisalo, Marjatta ^e   Flochová, Emília ^f   Vakkila, Jukka ^a   Arstila, Petteri ^g   Porkka, Kimmo ^a   Mustjoki, Satu ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f Martinska Fakultna Nemocnica   (Slovakia)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; CD3 ANTIGEN; CD45 ANTIGEN; CYTOKINE; IMMUNOLOGIC FACTOR;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; MOLECULAR GENETICS; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; AMINO ACID SEQUENCE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; TIME;

ADULT; AMINO ACID SEQUENCE; ANTIGENS, CD3; ANTIGENS, CD45; BASE SEQUENCE; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT, T-LYMPHOCYTE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REMISSION INDUCTION; TIME FACTORS; YOUNG ADULT;

EID: 79961240453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023022     Document Type: Article

References (47)

1. Deininger MW, Goldman JM, Melo JV, (2000) The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356.
2. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, et al. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054-1061.
3. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270.
4. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259.
5. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, et al. (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109: 58-60.
6. Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K, (2011) Interferon alpha for Treatment of Chronic Myeloid Leukemia. Curr Drug Targets 12: 420-428.
7. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114: 532-538.
8. Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, et al. (1992) Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79: 1920-1923.
9. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, et al. (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363: 2511-2521.
10. Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, et al. (2011) Pegylated IFN-alpha2a combined to imatinib mesylate 600 mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600 mg daily alone. Leuk Res 35: 80-86.
11. Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, et al. (2010) The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 95: 1415-1419.
12. Burchert A, Muller MC, Kostrewa P, Erben P, Bostel T, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28: 1429-1435.
13. Andrews DF 3rd, Singer JW, Collins SJ, (1987) Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines. Cancer Res 47: 6629-6632.
14. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, et al. (1991) Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78: 499-505.
15. Bhatia R, McCarthy JB, Verfaillie CM, (1996) Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87: 3883-3891.
16. Hochhaus A, Yan XH, Willer A, Hehlmann R, Gordon MY, et al. (1997) Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia. Leukemia 11: 933-939.
17. Pane F, Mostarda I, Selleri C, Salzano R, Raiola AM, et al. (1999) BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients. Blood 94: 2200-2207.
18. Deng M, Daley GQ, (2001) Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood 97: 3491-3497.
19. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, et al. (1998) Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 12: 455-462.
20. Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, et al. (1998) Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 12: 155-163.
21. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, et al. (2003) Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101: 259-264.
22. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, et al. (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458: 904-908.
23. Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, et al. (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20: 214-220.
24. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, et al. (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98: 3074-3081.
25. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, et al. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13: 110-118.
26. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, et al. (2010) Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116: 772-782.
27. Breit TM, Wolvers-Tettero IL, van Dongen JJ, (1994) Unique selection determinant in polyclonal V delta 2-J delta 1 junctional regions of human peripheral gamma delta T lymphocytes. J Immunol 152: 2860-2864.
28. Padovan E, Spagnoli GC, Ferrantini M, Heberer M, (2002) IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 71: 669-676.
29. Barrett AJ, Savani BN, (2009) Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia 23: 53-58.
30. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, et al. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365: 657-662.
31. Rojas JM, Knight K, Wang L, Clark RE, (2007) Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21: 2287-2295.
32. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, et al. (2003) Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102: 2892-2900.
33. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, et al. (2007) Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 21: 2145-2152.
34. Yong AS, Keyvanfar K, Hensel N, Eniafe R, Savani BN, et al. (2009) Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113: 875-882.
35. Rohon P, Porkka K, Mustjoki S, (2010) Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 85: 387-398.
36. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, et al. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23: 1398-1405.
37. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM, (1999) A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59: 2675-2681.
38. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, et al. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6: 1018-1023.
39. Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, et al. (2010) PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 5: e11770.
40. Hayday AC, (2000) [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026.
41. Rey J, Veuillen C, Vey N, Bouabdallah R, Olive D, (2009) Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med 15: 275-284.
42. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR, (2002) Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 23: 14-18.
43. Siegers GM, Felizardo TC, Mathieson AM, Kosaka Y, Wang XH, et al. (2011) Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic ph leukemia model. PLoS One 6: e16700.
44. Saudemont A, Jouy N, Hetuin D, Quesnel B, (2005) NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 105: 2428-2435.
45. Rothenberg ME, Hogan SP, (2006) The eosinophil. Annu Rev Immunol 24: 147-174.
46. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, et al. (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63: 7451-7461.
47. Usuki K, Yokoyama K, Nagamura-Inoue T, Ito A, Kida M, et al. (2009) CD8+ memory T cells predominate over naive T cells in therapy-free CML patients with sustained major molecular response. Leuk Res 33: e164-165.